Literature DB >> 7514011

Basic FGF and IGF-I promote differentiation of human SH-SY5Y neuroblastoma cells in culture.

E Lavenius1, V Parrow, E Nånberg, S Påhlman.   

Abstract

Phorbolester-triggered differentiation of SH-SY5Y neuroblastoma cells requires serum and a prolonged activation of protein kinase C (PKC). Under serum-free conditions development of a mature phenotype requires phorbolester in combination with a member of either the insulin-like growth factor (IGF) or the platelet-derived growth factor family. Here we report that basic and acidic fibroblast growth factor (FGF) and epidermal growth factor, but not nerve growth factor, synergistically potentiate phorbolester-induced differentiation. Alone these factors induced a mitogenic response which varied in magnitude, with basic FGF and IGF-I being the two most potent mitogens. However, a combination of basic FGF and IGF-I induced differentiation as judged by morphology and the increase in growth associated protein (GAP-43) and neuropeptide tyrosine mRNA levels. In contrast to the phenotype obtained in the presence of phorbolester, bFGF and IGF-I-treated SH-SY5Y cells retained their capacity to proliferate. Finally, in these cells, the phosphorylation of the endogenous PKC substrate, myristoylated alanine-rich C-kinase substrate (MARCKS), was slightly increased during several days, suggesting an involvement of PKC in the bFGF and IGF-I-induced differentiation.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7514011     DOI: 10.3109/08977199409019601

Source DB:  PubMed          Journal:  Growth Factors        ISSN: 0897-7194            Impact factor:   2.511


  8 in total

1.  Effects of gamma-IFN and NGF on subpopulations in a human neuroblastoma cell line: flow cytometric and morphological analysis.

Authors:  J Ridge; D A Terle; E Dragunsky; I Levenbook
Journal:  In Vitro Cell Dev Biol Anim       Date:  1996-04       Impact factor: 2.416

2.  IGF-2/IGF-1R signaling has distinct effects on Sox1, Irx3, and Six3 expressions during ES cell derived-neuroectoderm development in vitro.

Authors:  Nozomu Takata; Eriko Sakakura; Yoshiki Sasai
Journal:  In Vitro Cell Dev Biol Anim       Date:  2016-03-08       Impact factor: 2.416

3.  Multiple protein kinases determine the phosphorylated state of the small heat shock protein, HSP27, in SH-SY5Y neuroblastoma cells.

Authors:  Linda A Dokas; Amy M Malone; Frederick E Williams; Surya M Nauli; William S Messer
Journal:  Neuropharmacology       Date:  2011-02-19       Impact factor: 5.250

4.  Type III TGF-β receptor promotes FGF2-mediated neuronal differentiation in neuroblastoma.

Authors:  Erik H Knelson; Angela L Gaviglio; Alok K Tewari; Michael B Armstrong; Karthikeyan Mythreye; Gerard C Blobe
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

5.  Stromal heparan sulfate differentiates neuroblasts to suppress neuroblastoma growth.

Authors:  Erik H Knelson; Angela L Gaviglio; Jasmine C Nee; Mark D Starr; Andrew B Nixon; Stephen G Marcus; Gerard C Blobe
Journal:  J Clin Invest       Date:  2014-06-17       Impact factor: 14.808

6.  PKCepsilon, via its regulatory domain and independently of its catalytic domain, induces neurite-like processes in neuroblastoma cells.

Authors:  R Zeidman; B Löfgren; S Pâhlman; C Larsson
Journal:  J Cell Biol       Date:  1999-05-17       Impact factor: 10.539

7.  FGF1 protects neuroblastoma SH-SY5Y cells from p53-dependent apoptosis through an intracrine pathway regulated by FGF1 phosphorylation.

Authors:  Caroline Pirou; Fatemeh Montazer-Torbati; Nadège Jah; Elisabeth Delmas; Christelle Lasbleiz; Bernard Mignotte; Flore Renaud
Journal:  Cell Death Dis       Date:  2017-08-31       Impact factor: 8.469

8.  Transcription factor activating protein 4 is synthetically lethal and a master regulator of MYCN-amplified neuroblastoma.

Authors:  Shuobo Boboila; Gonzalo Lopez; Jiyang Yu; Debarshi Banerjee; Angela Kadenhe-Chiweshe; Eileen P Connolly; Jessica J Kandel; Presha Rajbhandari; Jose M Silva; Andrea Califano; Darrell J Yamashiro
Journal:  Oncogene       Date:  2018-06-07       Impact factor: 9.867

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.